Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  ziv-aflibercept
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-17 of 17 for your search:
Start Over
Phase I/II Study of Capecitabine Plus Aflibercept to Treat Metastatic Colorectal Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: Pro00037688, NCT01661972
Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 16
Sponsor: NCI
Protocol IDs: NCI-2011-02498, CHNMC-PHII-107, CDR0000690654, PhII-107, 8628, N01CM00038, N01CM00070, N01CM00071, N01CM62209, P30CA033572, NCT01258855
Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: OSU 11182, NCI-2012-01167, NCT01652196
Adjuvant Aflibercept for Metastatic Colorectal Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: BrUOG C261, NCT01669720
FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 12-401, NCT01747551
Study to Identify Biomarkers of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Q-CROC-04, NCT02045030
Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: Over 18
Sponsor: Other
Protocol IDs: 1309014302, 2012-AFL-18, NCT02046538
Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2014-00642, 2013-0954, 9604, N01CM00039, P30CA016672, NCT02101918
Clinical Trial of Combination Chemotherapy With Aflibercept in Patients With Advanced Colorectal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: HE 6A/13, 2013-002567-26, NCT02129257
Metastatic Colorectal Cancer Treated With First-line Aflibercept-based Treatment
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: PULSAR-1303, 2013-004540-33, NCT02173990
Efficacy and Safety of Aflibercept in Combination With FOLFIRI Chemotherapy as 1st Line Treatment for Patients With Metastatic Colorectal Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: FFCD 1302, NCT02181556
PERMAD: Personalized Marker-driven Early Switch to Aflibercept in Patients With Metastatic Colorectal Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: PERMAD, 2012-005657-24, NCT02331927
Induction FOLFOX With or Without Aflibercept Followed by Chemoradiation in High Risk Locally Advanced Rectal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to less than 70
Sponsor: Other
Protocol IDs: GEMCAD-1402, NCT02340949
Phase 1 Study Testing the Combination of Aflibercept and Capecitabine in Metastatic Digestive and Breast Cancers
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Mom1-AD12, 2012-005169-11, NCT01843725
MLN0128 and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2014-01107, 2013-0665, 9585, P30CA016672, U01CA062461, UM1CA186688, NCT02159989
Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas
Phase: Phase I
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 140150, 14-C-0150, NCT02192541
Pembrolizumab and Ziv-aflibercept in Treating Patients With Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2014-01984, 9676, P30CA006516, U01CA062490, UM1CA186709, NCT02298959
Start Over